PitchBook Report – Emerging Space Brief: Longevity Tech
Click here to view Pitchbook’s report featuring Bakar Labs tenant company Cyclarity Therapeutics.
Big money, long timelines: Billionaire-backed startups bet on the business of living longer
The longevity tech sector is betting big on the science of staying young. While no antiaging breakthroughs have reached the market yet, 2024 marked a rebound in venture investment, with startups raising nearly $300 million as they double down on epigenetic reprogramming and senolytics. Backed by billionaire visionaries like Jeff Bezos and Sam Altman, these companies are targeting the root causes of aging—not just its symptoms.
Standout deals include NewLimit’s $72.3 million raise to advance epigenetic rejuvenation and Cyclarity Therapeutics’ $10.3 million round to push forward its senolytic platform. Despite regulatory gray areas and a long road to clinical validation, momentum is building as longevity biotech shifts from speculative science to a potential cornerstone of future healthcare.
